# Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

> PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15789272-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15789272-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15789272-lanreotide-v1.json
- Content SHA-256: `b4c197e60c69ce49036fc29499b052a1bfcb451ebbd52bc56d2b4c59b34af771`

## Claims and source pins

### Headline

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

### Summary

PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

### Paragraph 1

PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

## Sources

<a id="source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c"></a>
- **Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). · retained source version 1:2026-01-28:current:d803d8ef110c4653974c3a80952a3dd6ed0c8cc7285052ddf28a26605502340c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15789272/) (`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15789272-lanreotide-v1.json SHA-256: b4c197e60c69ce49036fc29499b052a1bfcb451ebbd52bc56d2b4c59b34af771.